Deutsch English Français

Contact

EP4132649

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP4132649

EP4132649 - CRYSTALLINE FORMS OF A TYK2 INHIBITOR [Right-click to bookmark this link]
Status	Request for examination was made Status updated on 13.01.2023 Database last updated on 18.09.2024
Former	The international publication has been made Status updated on 16.10.2021
Former	unknown Status updated on 17.04.2021
Most recent event Tooltip	28.03.2024	New entry: Renewal fee paid
Applicant(s)	For all designated states Sareum Limited Unit 2A, Langford Arch London Road Pampisford Cambridge, Cambridgeshire CB22 3FX / GB
	[2023/07]
Inventor(s)	01 / READER, John Charles c/o Sareum Limited Unit 2A, Langford Arch London Road, Pampisford Cambridge CB22 3FX / GB
	02 / MARSHALL, Jamie Conor UK Dudley Sterling Place Dudley Cramlington Northumberland NE23 7QG / GB
	03 / MYKYTIUK, John UK Dudley Sterling Place Dudley Cramlington Northumberland NE23 7QG / GB
	04 / NORTHEN, Julian Scott c/o Onxy Scientific Limited Units 97 & 98 Silverbriar Sunderland Enterprise Park East Sunderland, Tyne and Wear SR5 2TQ / GB
	[2023/07]
Representative(s)	Bajjon, Alexander, et al Schlich 9 St. Catherine's Road Littlehampton, West Sussex BN17 5HS / GB
	[2023/07]
Application number, filing date	21717041.4	06.04.2021
	[2023/07]
	WO2021EP58864
Priority number, date	GB20200005114	07.04.2020 Original published format: GB 202005114
	[2023/07]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2021204762
	Date:	14.10.2021
	Language:	EN
	[2021/41]
	Type:	A1 Application with search report
	No.:	EP4132649
	Date:	15.02.2023
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 14.10.2021 takes the place of the publication of the European patent application.
	[2023/07]
Search report(s)	International search report - published on:	EP	14.10.2021
Classification	IPC:	A61P29/00, A61K31/541, A61P37/00, C07D263/48	[2023/07]
	CPC:	C07D263/48 (EP,IL,KR,US); A61K31/541 (KR); A61P29/00 (EP,IL); A61P37/00 (EP,IL); C07B2200/13 (KR,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/07]
Title	German:	KRISTALLINE FORMEN EINES TYK2-INHIBITORS	[2023/07]
	English:	CRYSTALLINE FORMS OF A TYK2 INHIBITOR	[2023/07]
	French:	FORMES CRISTALLINES D'UN INHIBITEUR DE TYK2	[2023/07]
Entry into regional phase	25.08.2022	National basic fee paid
	25.08.2022	Designation fee(s) paid
	25.08.2022	Examination fee paid
Examination procedure	25.08.2022	Examination requested [2023/07]
	25.08.2022	Date on which the examining division has become responsible
	06.04.2023	Amendment by applicant (claims and/or description)
Fees paid	Renewal fee
	27.03.2023	Renewal fee patent year 03
	27.03.2024	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[AD]WO2018073438 (SAREUM LTD [GB]) [AD] 1-18 * claim 5; compound 29 *;
		[IDP]WO2020074461 (SAREUM LTD [GB]) [IDP] 1-18* claims 2, 4-9; compound 1F *
	by applicant	WO2008139161
		WO2008156726
		WO2009155156
		WO2010005841
		WO2010011375
		WO2010055304
		WO2011113802
		WO2012000970
		EP2634185
		WO2014007466
		WO2014074661
		WO2015032423
		WO2016027195
		WO2018073438
		- HANKSHUNTER, FASEB J.,, (19950000), vol. I and II, pages 576 - 596
		- KNIGHTON et al., Science, (19910000), vol. 253, pages 407 - 414
		- VELAZQUEZ et al., Cell, (19920000), vol. 70, pages 313 - 322
		- KUNZ et al., Cell, (19930000), vol. 73, pages 585 - 596
		- GARCIA-BUSTOS et al., EMBO J., (19940000), vol. 13, pages 2352 - 2361
		- YAMAOKA et al., "The Janus kinases (Jaks", Genome Biology, (20040000), vol. 5, no. 12, page 253
		- GRACIE, J. A. et al., "lnterleukin-12 induces interferon- gamma-dependent switching of IgG alloantibody subclass", Eur. J. Immunol, (19960000), vol. 26, pages 1217 - 1221
		- SCHRODER, K. et al., "Interferon-gamma: an overview of signals, mechanisms and functions", J. Leukoc. Biol, (20040000), vol. 75, no. 2, doi:10.1189/jlb.0603252, pages 163 - 189, XP009031305 DOI: http://dx.doi.org/10.1189/jlb.0603252
		- KYTTARIS, V.C. et al., "Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice", J. Immunol, (20100000), vol. 184, pages 4605 - 4609
		- HONG, K. et al., "IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis like skin disorder", J. Immunol, (19990000), vol. 162, pages 7480 - 7491, XP002188301
		- HUE, S. et al., "Interleukin-23 drives innate and T cell-mediated intestinal inflammation", J. Exp. Med., (20060000), vol. 203, doi:10.1084/jem.20061099, pages 2473 - 2483, XP055111922 DOI: http://dx.doi.org/10.1084/jem.20061099
		- CUA, D.J. et al., "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, (20030000), vol. 421, doi:10.1038/nature01355, pages 744 - 748, XP002971969 DOI: http://dx.doi.org/10.1038/nature01355
		- MURPHY, C.A. et al., "Divergent pro- and anti-inflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation", J. Exp. Med, (20030000), vol. 198, pages 1951 - 1957
		- KARAGHIOSOFF et al., Immunity, (20000000), vol. 13, pages 561 - 671
		- MINEGISHI et al., Immunity, (20060000), vol. 25, pages 745 - 755
		- KREINS et al., The Journal of Experimental Medicine, (20150824), pages 1 - 22
		- SIGURDSSON et al., Am. J. Hum. Genet., (20050000), vol. 76, pages 528 - 537
		- GRAHAM et al., Rheumatology, (20070000), vol. 46, pages 927 - 930
		- HELLQUIST et al., J. Rheumatol., (20090000), vol. 36, pages 1631 - 1638
		- JARVINEN et al., Exp. Dermatol, (20100000), vol. 19, pages 123 - 131
		- MERO et al., Eur. J. Hum. Genet., (20090000), vol. 18, pages 1309 - 1313
		- SATO et al., J. Clin. Immunol., (20090000), vol. 29, pages 815 - 825
		- SHAW et al., PNAS, (20030000), vol. 100, pages 11594 - 11599
		- SPACH et al., J. Immunol., (20090000), vol. 182, pages 7776 - 7783
		- OYAMADA et al., J. Immunol., vol. 183, pages 7539 - 7546
		- SCHISCHMANOFF et al., Sarcoidosis Vase. Diffuse.,, (20060000), vol. 23, no. 2, pages 101 - 7
		- GHORESCHI et al., Immunol Rev, (20090000), vol. 228, pages 273 - 287
		- GHORESCHI et al., Nature Immunol., (20090000), vol. 4, pages 356 - 360
		- HANCOCK et al., J. Pharm. Sci., (19970000), vol. 86, page 1
		- FIRESTEIN, Nature, (20030000), vol. 423, pages 356 - 361
		- ASAKURA et al., World J. Gastroenterol, (20070000), vol. 13, no. 15, pages 2145 - 9
		- SCHON et al., New Engl. J. Med., (20050000), vol. 352, pages 1899 - 1912
		- D'CRUZ et al., Lancet, (20070000), vol. 369, no. 9561, pages 587 - 596
		- MORI et al., Kobe J. Med. Sci., (20160000), vol. 62, no. 4, pages E79 - E88
		- VAN DER FITS, The Journal of Immunology, (20090000), vol. 182, pages 5836 - 5845
		- LIN et al., PLOS ONE
		- BAN et al., European Journal of Human Genetics, (20090000), vol. 17, pages 1309 - 1313
		WO2019EP77118

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p